0 CHECKOUT

Ageing - Pipeline Review, H1 2015

  • ID: 3259619
  • April 2015
  • 49 pages
  • Global Markets Direct
1 of 4

Ageing - Pipeline Review, H1 2015

Summary

This, ‘Ageing - Pipeline Review, H1 2015’, provides an overview of the Ageing’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Ageing Overview
Therapeutics Development
Pipeline Products for Ageing - Overview
Pipeline Products for Ageing - Comparative Analysis
Ageing - Therapeutics under Development by Companies
Ageing - Therapeutics under Investigation by Universities/Institutes
Ageing - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Ageing - Products under Development by Companies
Ageing - Products under Investigation by Universities/Institutes
Ageing - Companies Involved in Therapeutics Development
Bioo Therapeutics
Neuralstem, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
Ageing - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BIOO-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIOO-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Ageing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metformin + sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MG-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMP-26051 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMP-26052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RCS-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Alzheimer's Disease and Ageing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ageing - Recent Pipeline Updates
Ageing - Dormant Projects
Ageing - Product Development Milestones
Featured News & Press Releases
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ageing, H1 2015
Number of Products under Development for Ageing - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Ageing - Pipeline by Bioo Therapeutics, H1 2015
Ageing - Pipeline by Neuralstem, Inc., H1 2015
Ageing - Pipeline by RepliCel Life Sciences, Inc., H1 2015
Ageing - Pipeline by RXi Pharmaceuticals Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Ageing Therapeutics - Recent Pipeline Updates, H1 2015
Ageing - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Ageing, H1 2015
Number of Products under Development for Ageing - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Bioo Therapeutics
Neuralstem, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.